Related Experiment Video
Updated: Aug 9, 2025

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
Published on: May 9, 2025
Nucleoside Analogs That Inhibit SARS-CoV-2 Replication by Blocking Interaction of Virus Polymerase with RNA
Elena Matyugina1, Ivan Petushkov2, Sergei Surzhikov1
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Abstract:
The SARS-CoV-2 betacoronavirus pandemic has claimed more than 6.5 million lives and, despite the development and use of COVID-19 vaccines, remains a major global public health problem. The development of specific drugs for the treatment of this disease remains a very urgent task. In the context of a repurposing strategy, we previously screened a library of nucleoside analogs showing different types of biological activity against the SARS-CoV-2 virus. The screening revealed compounds capable of inhibiting the reproduction of SARS-CoV-2 with EC50 values in the range of 20-50 µM. Here we present the design and synthesis of various analogs of the leader compounds, the evaluation of their cytotoxicity and antiviral activity against SARS-CoV-2 in cell cultures, as well as experimental data on RNA-dependent RNA polymerase inhibition. Several compounds have been shown to prevent the interaction between the SARS-CoV-2 RNA-dependent RNA polymerase and the RNA substrate, likely inhibiting virus replication. Three of the synthesized compounds have also been shown to inhibit influenza virus. The structures of these compounds can be used for further optimization in order to develop an antiviral drug.
Insights
Researchers developed new nucleoside analogs to combat SARS-CoV-2. Some compounds inhibit viral RNA polymerase and replication, with potential for treating COVID-19 and influenza.
Area of Science:
- Virology
- Medicinal Chemistry
- Drug Discovery
Background:
- The COVID-19 pandemic caused by SARS-CoV-2 remains a global health crisis.
- Developing effective antiviral drugs for SARS-CoV-2 is a critical unmet need.
- Nucleoside analogs are a promising class of antiviral agents.
Purpose of the Study:
- To design and synthesize novel nucleoside analogs.
- To evaluate their antiviral activity against SARS-CoV-2 in vitro.
- To investigate their mechanism of action, including RNA-dependent RNA polymerase inhibition.
Main Methods:
- Drug repurposing strategy and screening of nucleoside analogs.
- Synthesis of novel analogs based on lead compounds.
- Cytotoxicity assays and antiviral activity evaluation in cell cultures.
- Inhibition assays targeting SARS-CoV-2 RNA-dependent RNA polymerase.
Main Results:
- Identified lead compounds inhibiting SARS-CoV-2 replication with EC50 values of 20-50 µM.
- Synthesized and tested various analogs for cytotoxicity and antiviral efficacy.
- Several compounds demonstrated inhibition of SARS-CoV-2 RNA-dependent RNA polymerase.
- Three synthesized compounds also exhibited activity against influenza virus.
Conclusions:
- Novel nucleoside analogs show promise as antiviral agents against SARS-CoV-2.
- Inhibition of viral RNA-dependent RNA polymerase is a likely mechanism of action.
- These compounds represent valuable scaffolds for further optimization into clinical antiviral drugs.
- Potential for broad-spectrum antiviral activity, including influenza.
Related Concept Videos
Viruses with RNA Genomes
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Subviral Agents
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Retrovirus Life Cycles
Size and Structure of Viral Genomes

